| Literature DB >> 35235188 |
Marcus Powers1,2, John Baines3, Robert Crane4, Chantelle Fisher4, Stephen Gibson4, Linda Marsh4, Bronwyn Oar4, Ariadne Shoobridge4,5, Emily Simpson-Page6, Marchant Van der Walt4, Glenn de Vine4.
Abstract
Magnetic resonance-guided radiotherapy technology is relatively new and commissioning publications, quality assurance (QA) protocols and commercial products are limited. This work provides guidance for implementation measurements that may be performed on the Elekta Unity MR-Linac (Elekta, Stockholm, Sweden). Adaptations of vendor supplied phantoms facilitated determination of gantry angle accuracy and linac isocentre, whereas in-house developed phantoms were used for end-to-end testing and anterior coil attenuation measurements. Third-party devices were used for measuring beam quality, reference dosimetry and during treatment plan commissioning; however, due to several challenges, variations on standard techniques were required. Gantry angle accuracy was within 0.1°, confirmed with pixel intensity profiles, and MV isocentre diameter was < 0.5 mm. Anterior coil attenuation was approximately 0.6%. Beam quality as determined by TPR20,10 was 0.705 ± 0.001, in agreement with treatment planning system (TPS) calculations, and gamma comparison against the TPS for a 22.0 × 22.0 cm2 field was above 95.0% (2.0%, 2.0 mm). Machine output was 1.000 ± 0.002 Gy per 100 MU, depth 5.0 cm. During treatment plan commissioning, sub-standard results indicated issues with machine behaviour. Once rectified, gamma comparisons were above 95.0% (2.0%, 2.0 mm). Centres which may not have access to specialized equipment can use in-house developed phantoms, or adapt those supplied by the vendor, to perform commissioning work and confirm operation of the MRL within published tolerances. The plan QA techniques used in this work can highlight issues with machine behaviour when appropriate gamma criteria are set.Entities:
Keywords: Commissioning; Elekta Unity; MR-Linac
Mesh:
Year: 2022 PMID: 35235188 PMCID: PMC9239956 DOI: 10.1007/s13246-022-01113-7
Source DB: PubMed Journal: Phys Eng Sci Med ISSN: 2662-4729
Fig. 1A schematic of the Elekta Unity MR-Linac, courtesy of Elekta, showing (a) the straight-through waveguide, (b) the gantry ring, (c) the primary radiation beam passing through (d) the coil system embedded in the magnet cryostat, (e) the patient positioning system and (f) the MVI. The IEC61217 coordinate system is shown, and for the head-first-supine patient orientation, B0 is in the craniocaudal direction (negative Y)
Fig. 2Images of the Elekta supplied (a) MV alignment phantom (b) QA Platform with the PTW Octavius 1500MR array and solid water stack on top (c) cryostat characterisation tool, as well as the in-house developed (d) cylindrical phantom used for rotational output measurements and (e) acrylic phantom used for E2E workflows
Fig. 3MVI images of the superior outer ring of ballbearings on the MV alignment phantom. Gantry angles of (a) 270°, (b) 0.0°, (c) 0.2°, (d) 0.3°, (e) 1.0° and (f) 359.0° are presented
Fig. 4Comparison of profiles taken left to right from MVI images for the ballbearings at (a) G0 and G0.1 and (b) G0 and G0.3
MV isocentre results for the various methodologies, analyses and magnetic field environments
| Equipment and method | Magnetic field [T] | Isocentre diameter [mm] |
|---|---|---|
| CCT + RIT analysis | 1.5 | 0.45 |
| MV alignment + RIT analysis | 1.5 | 0.42 |
| CCT + in-house analysis | 1.5 | 0.34 |
| MV alignment + in-house analysis | 1.5 | 0.38 |
| MV alignment + in-house analysis | 0.0 | 0.32 |
| Spoke shot with copper ring | 1.5 | 0.36 |
| Spoke shot with copper ring | 0.0 | 0.24 |
| Spoke shot without copper ring | 0.0 | 0.28 |
The use of the CCT with the RIT analysis was performed by Elekta during DAT and the use of the MV alignment phantom and RIT analysis is performed during the physics validation stage, and is consistent with that discussed by Snyder et al. [4]
Measured and calculated anterior coil attenuation as a function of gantry angle
| Gantry angle [°] | Measured attenuation [%] | Monaco attenuation [%] |
|---|---|---|
| 75.0 | 0.0 | 0.0 |
| 60.0 | 0.6 | 0.8 |
| 45.0 | 0.6 | 0.9 |
| 30.0 | 0.5 | 1.0 |
| 0.0 | 0.5 | 0.7 |
| 345.0 | 0.4 | 0.8 |
| 330.0 | 0.7 | 0.9 |
| 315.0 | 0.6 | 0.8 |
| 300.0 | 0.6 | 0.7 |
| 285.0 | 0.0 | 0.0 |
Fig. 5Dose maps for 22.0 × 22.0 cm2 fields measured on the Octavius 1500MR array and compared to TPS calculations in Verisoft using gamma analysis at 2.0%, 2.0 mm criteria for (a) the original commissioning magnetron and (b) with the new magnetron. Regions of hot/cold failure are indicated by the red/blue dots, respectively
Fig. 6MVI images of segments for one of the in-house developed stereo plans. (a) Shows one delivered segment with the guard leaf error present and (b) shows the same segment with the error removed, matching that which was planned as indicated by (c) the beams-eye-view from Monaco TPS. All scales are in centimetres
Gamma results for perpendicular deliveries to the 1500MR array of the Elekta supplied TG119 plans and the two in-house developed stereotactic plans
| Plan | Pre-fix | Post-fix | ||
|---|---|---|---|---|
| 2%, 2 mm | 3%, 3 mm | 2%, 2 mm | 3%, 3 mm | |
| Abdomen | 99.2 | 100.0 | 97.9 | 100.0 |
| Head and neck | 94.2 | 100.0 | 95.8 | 100.0 |
| Lung | 96.4 | 100.0 | 96.1 | 100.0 |
| Multi-target | 77.8 | 96.2 | 95.6 | 99.8 |
| Prostate | 97.4 | 100.0 | 97.8 | 100.0 |
| Prostate_2 | 84.8 | 93.1 | 99.6 | 100.0 |
| Prostate_7fld | 88.4 | 94.8 | 100.0 | 100.0 |
| Prostate_9fld | 90.9 | 98.2 | 99.5 | 100.0 |
| Prostate_11fld | 96.5 | 100.0 | 100.0 | 100.0 |
| Stereo 1 | 94.0 | 98.5 | 100.0 | 100.0 |
| Stereo 2 | 71.2 | 82.0 | 98.6 | 100.0 |
Gamma results for perpendicular deliveries to film of the Elekta supplied TG119 plans and the two in-house developed stereotactic plans
| Plan | Pre-fix | Post-fix | ||
|---|---|---|---|---|
| 2%, 2 mm | 3%, 3 mm | 2%, 2 mm | 3%, 3 mm | |
| Abdomen | 96.2 | 99.8 | 96.0 | 99.7 |
| Head and neck | 91.7 | 95.7 | 99.7 | 100.0 |
| Lung | 68.8 | 86.0 | 99.9 | 100.0 |
| Multi-target | 77.4 | 92.9 | 98.0 | 99.9 |
| Prostate | 97.0 | 99.9 | 99.2 | 100.0 |
| Prostate_2 | 75.7 | 90.5 | 97.6 | 99.7 |
| Prostate_7fld | 92.7 | 96.1 | 95.7 | 99.8 |
| Prostate_9fld | 95.2 | 99.3 | 97.0 | 100.0 |
| Prostate_11fld | 98.9 | 100.0 | 98.2 | 99.8 |
| Stereo 1 | 70.2 | 92.1 | 97.3 | 99.3 |
| Stereo 2 | 95.2 | 95.2 | ||
Gamma results for composite deliveries to film of the Elekta supplied TG119 plans and the two in-house developed stereotactic plans
| Plan | Pre-fix | Post-fix | ||
|---|---|---|---|---|
| 2%, 2 mm | 3%, 3 mm | 2%, 2 mm | 3%, 3 mm | |
| Abdomen | 74.5 | 94.7 | 96.5 | 99.7 |
| Head and neck | 92.3 | 99.1 | 97.4 | 99.8 |
| Lung | 80.4 | 97.4 | 98.0 | 100.0 |
| Multi-target | 79.1 | 94.8 | 97.3 | 99.8 |
| Prostate | 97.9 | 99.9 | 95.5 | 99.5 |
| Prostate_2 | 87.4 | 97.1 | 96.9 | 99.9 |
| Prostate_7fld | 95.1 | 99.3 | ||
| Prostate_9fld | 98.0 | 100.0 | 98.8 | 100.0 |
| Prostate_11fld | 99.5 | 100.0 | ||
| Stereo 1 | 81.2 | 96.3 | 97.8 | 99.6 |
| Stereo 2 | 96.0 | 98.7 | ||